Replies to post #246575 on Biotech Values

[DewDiligence]

I don't disagree with your numbers. The calculation in the tweet I cited is a worst-case scenario where 54.5% of the cumulative royalties through 2032 equal or exceed $284M. In that case, ENTA's transaction will cause it to forgo a cumulative $84M, which has an NPV of around $60M (depending on your discount rate).